326 related articles for article (PubMed ID: 12668489)
1. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease.
Blankenberg S; Rupprecht HJ; Poirier O; Bickel C; Smieja M; Hafner G; Meyer J; Cambien F; Tiret L;
Circulation; 2003 Apr; 107(12):1579-85. PubMed ID: 12668489
[TBL] [Abstract][Full Text] [Related]
2. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study.
Lubos E; Schnabel R; Rupprecht HJ; Bickel C; Messow CM; Prigge S; Cambien F; Tiret L; Münzel T; Blankenberg S
Eur Heart J; 2006 Jan; 27(2):150-6. PubMed ID: 16230310
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
5. The T(-786)C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high-risk patients.
Rossi GP; Maiolino G; Zanchetta M; Sticchi D; Pedon L; Cesari M; Montemurro D; De Toni R; Zavattiero S; Pessina AC
J Am Coll Cardiol; 2006 Sep; 48(6):1166-74. PubMed ID: 16979000
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease.
Opstad TB; Pettersen AA; Weiss TW; Akra S; Øvstebø R; Arnesen H; Seljeflot I
Clin Chim Acta; 2012 Jan; 413(1-2):113-20. PubMed ID: 21963461
[TBL] [Abstract][Full Text] [Related]
7. Mild depression versus C-reactive protein as a predictor of cardiovascular death: a three year follow-up of patients with stable coronary artery disease.
Rallidis LS; Varounis C; Sourides V; Charalampopoulos A; Kotakos C; Liakos G; Dagres N; Apostolou T; Anastasiou-Nana M
Curr Med Res Opin; 2011 Jul; 27(7):1407-13. PubMed ID: 21568834
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease.
Hlatky MA; Ashley E; Quertermous T; Boothroyd DB; Ridker P; Southwick A; Myers RM; Iribarren C; Fortmann SP; Go AS;
Am Heart J; 2007 Dec; 154(6):1043-51. PubMed ID: 18035073
[TBL] [Abstract][Full Text] [Related]
9. Association of MMP-9 gene polymorphisms with atrial fibrillation in hypertensive heart disease patients.
Gai X; Lan X; Luo Z; Wang F; Liang Y; Zhang H; Zhang W; Hou J; Huang M
Clin Chim Acta; 2009 Oct; 408(1-2):105-9. PubMed ID: 19665460
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
[TBL] [Abstract][Full Text] [Related]
11. Functional -1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users.
Tu HF; Wu CH; Kao SY; Liu CJ; Liu TY; Lui MT
J Oral Pathol Med; 2007 Aug; 36(7):409-14. PubMed ID: 17617834
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial.
Brown DL; Desai KK; Vakili BA; Nouneh C; Lee HM; Golub LM
Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):733-8. PubMed ID: 14962945
[TBL] [Abstract][Full Text] [Related]
13. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study.
Schnabel R; Lubos E; Rupprecht HJ; Espinola-Klein C; Bickel C; Lackner KJ; Cambien F; Tiret L; Münzel T; Blankenberg S
J Am Coll Cardiol; 2006 Feb; 47(3):552-8. PubMed ID: 16458135
[TBL] [Abstract][Full Text] [Related]
14. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
15. Prognosis by C-reactive protein and matrix metalloproteinase-9 levels in stable coronary heart disease during 15 years of follow-up.
Eldrup N; Kragelund C; Steffensen R; Nordestgaard BG
Nutr Metab Cardiovasc Dis; 2012 Aug; 22(8):677-83. PubMed ID: 21194909
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-1 and matrix metalloproteinase-12 gene polymorphisms and the outcome of coronary artery disease.
Jguirim-Souissi I; Jelassi A; Slimani A; Addad F; Hassine M; Hamda KB; Najah M; Maatouk F; Rouis M; Slimane MN
Coron Artery Dis; 2011; 22(6):388-93. PubMed ID: 21606841
[TBL] [Abstract][Full Text] [Related]
17. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men.
Tuomainen AM; Nyyssönen K; Laukkanen JA; Tervahartiala T; Tuomainen TP; Salonen JT; Sorsa T; Pussinen PJ
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2722-8. PubMed ID: 17932311
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects.
Demacq C; de Souza AP; Machado AA; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2006 Mar; 365(1-2):183-7. PubMed ID: 16168399
[TBL] [Abstract][Full Text] [Related]
19. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study.
Sinning JM; Bickel C; Messow CM; Schnabel R; Lubos E; Rupprecht HJ; Espinola-Klein C; Lackner KJ; Tiret L; Münzel T; Blankenberg S;
Eur Heart J; 2006 Dec; 27(24):2962-8. PubMed ID: 17132649
[TBL] [Abstract][Full Text] [Related]
20. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects.
Anand DV; Lahiri A; Lim E; Hopkins D; Corder R
J Am Coll Cardiol; 2006 May; 47(9):1850-7. PubMed ID: 16682312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
